Chemistry: analytical and immunological testing – Nuclear magnetic resonance – electron spin resonance or other...
Reexamination Certificate
2009-01-20
2010-12-28
Gakh, Yelena G (Department: 1797)
Chemistry: analytical and immunological testing
Nuclear magnetic resonance, electron spin resonance or other...
C436S086000, C436S171000, C435S006120, C435S069900, C435S372000, C702S020000, C702S179000
Reexamination Certificate
active
07858389
ABSTRACT:
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer (NSCLC) patient is likely to benefit from a monoclonal antibody drug targeting an epidermal growth factor receptor pathway. A mass spectrum is obtained from a sample (e.g. blood sample) from the patient. One or more predefined pre-processing steps are performed on the mass spectrum. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained after the pre-processing steps have been performed. Such values are used in a classification algorithm using a training set comprising class-labeled spectra produced from samples from other patients to identify the patient as being likely to benefit from treatment with the drug.
REFERENCES:
patent: 7736905 (2010-06-01), Roder et al.
patent: 2005/0048547 (2005-03-01), Zhao et al.
patent: 2005/0164218 (2005-07-01), Agus et al.
patent: 2005/0267689 (2005-12-01), Tsypin
patent: 2006/0029574 (2006-02-01), Albitar et al.
patent: 2007/0231921 (2007-10-01), Röder et al.
patent: WO 2004/012588 (2004-02-01), None
patent: WO 2005/010492 (2005-02-01), None
patent: WO 2005/098445 (2005-10-01), None
Written Opinion of the International Searching Authority in PCT/US2007/007467 dated Nov. 8, 2007.
International Search Report in PCT Application Publication No. WO 2007/126758, published Nov. 8, 2007.
Fleming et al. “Windowed mass selection method: a new data processing algorithm for liquid chromatography-mass spectrometry data”, Journal of Chromatography A, vol. 849, pp. 71-85 (1999).
Senko et al., “Determination of monoisotopic masses and ion population for large biomolecules from resolved isotopic distribution”, Journal of the American Society for Mass Spectrometry, vol. 6, pp. 229-233 (1995).
Gras et al., “Improving protein identification from peptide mass fingerprinting through a parameterized multi-level scoring algorithm and an optimized peak detection”, Electrophoresis, vol. 20, pp. 3535-3550 (1999).
Metro, et al., “Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)”, Reviews on Recent Clinical Trials, vol. 1, No: 1, pp. 1-13 (2006).
Taguchi, et al., “Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study”, Journal of the National Cancer Institute, vol. 99, Issue 11, pp. 838-846 (2007).
Ladanyi, et al., “Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond”, Modern Pathology, vol. 21, pp. S16-S22 (2008).
Office Action dated Feb. 6, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
Amendment and pending claims filed Apr. 7, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
U.S. Appl. No. 12/321,393 filed Jan. 20, 2009.
U.S. Appl. No. 12/321,394 filed Jan. 20, 2009.
Extended European Search Report in EP 07754043.3, dated Jun. 8, 2009.
U.S. Office Action dated Aug. 25, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
Lynch et al.,Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib, The New England Journal of Medicine, vol. 350, No. 21, pp. 2129-2139 (2004).
Alfassi,On the Normalization of a Mass Spectrum for Comparison of Two Spectra, American Society for Mass Spectrometry, vol. 15, pp. 385-387 (2004).
Bhanot et al.,A Robust Meta-Classification Strategy for Cancer Detection from MS Data, Proteomics, vol. 6, pp. 592-604 (2006).
Koenker et al.,Quantile Smoothing Splines, Biometrika vol. 81, pp. 673-680 (1994).
Eilers,Parametric Time Warping, Analytical Chemistry, vol. 76, No. 2, pp. 401-411 (2004).
Extended European Search Report dated Aug. 25, 2010 in European Application No. 10003343.0.
Bhanot et al.A robust meta-classification strategy for cancer detection from MS dataProteomics, vol. 6, NR 2, pp. 592-607 (Jan. 2006).
Reyzer et al.MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery, Journal of Proteome Research vol. 4, No. 4, pp. 1138-1142 (2005).
Yanagisawa et al.Proteomic patterns of tumour subsets in non-small-cell lung cancer, The Lancet, vol. 362, pp. 433-439 (Aug. 9, 2003).
Grigorieva Julia
Röder Heinrich
Tsypin Maxim
Biodesix, Inc.
Gakh Yelena G
McDonnell Boehnen & Hulbert & Berghoff LLP
Xu Robert
LandOfFree
Selection of non-small-cell lung cancer patients for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selection of non-small-cell lung cancer patients for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selection of non-small-cell lung cancer patients for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152614